Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine vs Morphine for Postoperative Analgesia
NCT06949852Phase 3Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nalbuphine in postoperative pain (2 arms), sponsored by Yangtze River Pharmaceutical Group. Primary endpoint: Sum of Pain Intensity Difference at 48 hours. Started Aug 2024; status: completed.
02
Drugs
nalbuphine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06949852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949852.